The quality of dementia research in the U.K. is second only to the U.S., despite the low number of scientists working in this field, and finding a cure can be accelerated by increasing the number of dementia researchers and investment, according the Intellectual Property & Science business of Thomson Reuters. The findings are featured in an Alzheimer’s U.K. research report “Defeating Dementia.”
The analysis revealed the U.K. published more research on dementia than any other country except the U.S. and ranks second in the world after Sweden in citation impact, the number of times U.K. research is referenced in dementia studies around the globe. Despite its high performance and influence, dementia research capacity in the U.K. is low when compared to cancer, stroke and heart disease. For every dementia research scientist there are six who work on cancer.
“Research output and citation impact in scientific literature is an ideal way to measure the quality and capacity of dementia research,” said Karen Gurney, manager of bibliometric reporting at Thomson Reuters. “This project illuminated an interesting dementia-research landscape in the U.K., where this region is clearly playing an influential role despite its size.”
The research study was commissioned by the U.K.’s leading dementia research charity, Alzheimer’s Research U.K., in an effort to raise awareness and increase investment for the underfunded field. The data measuring the quality and size of dementia research in the U.K. was compiled by Thomson Reuters. Issued by Alzheimer’s U.K., the report also outlines 14 recommendations to the U.K.government based on feedback from scientists working in the field.
The report “makes a strong case for more investment in dementia research,” said Simon Ridley, head of research at Alzheimer’s Research U.K.
The report’s 14 recommendations are: